Benign Prostatic Hyperplasia (BPH) Clinical Trial
Official title:
Is Absorption of Irrigation Fluid a Problem in Thulium Laser Vaporization of the Prostate? A Prospective Investigation Using the Expired Breath Ethanol Test.
Verified date | February 2016 |
Source | Cantonal Hospital of St. Gallen |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Observational |
Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older
than 60 years.In cases with moderate to severe lower urinary tract symptoms (LUTS) monopolar
transurethral resection of the prostate (TUR-P) is the standard treatment. Especially in
frail patients, conventional TUR-P is associated with relevant and potentially deleterious
complications, e.g. TUR syndrome. Using isotonic saline, like in bipolar TUR-P and
transurethral laser vaporization (TUV-P), TUR syndrome can be prevented.
The short-term complication rate with the Thulium laser is similar to the rate described
after vaporisation with other laser systems18-23 and less than that with TUR-P.
Despite recent publications on the safety and complications with Thulium vaporisation of the
prostate, to the investigators knowledge, until now, no prospective trial has directly
assessed, whether absorption of irrigation fluid occurs and to what extent in Thulium Laser
vaporisation of the prostate.
The investigators therefore aim to investigate if absorption of irrigation fluid occurs
during Thulium Laser vaporisation of the prostate by expired breath ethanol test.
Status | Completed |
Enrollment | 57 |
Est. completion date | February 2016 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Men older than 40 - Patient must be a candidate for TUV-P - Refractory to medical therapy or patient is not willing to consider (further) medical treatment - Written informed consent Exclusion Criteria: - Mild symptoms (IPSS <8) - Urethral stenosis - Bladder diverticulum (>100ml) - Former alcoholic or chronic liver disease - Alcohol consumption 24h before operation |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Switzerland | Cantonal Hospital St. Gallen | St. Gallen |
Lead Sponsor | Collaborator |
---|---|
Daniel Stephan Engeler |
Switzerland,
Mordasini L, Abt D, Müllhaupt G, Engeler DS, Lüthi A, Schmid HP, Schwab C. Is absorption of irrigation fluid a problem in Thulium laser vaporization of the prostate? A prospective investigation using the expired breath ethanol test. BMC Urol. 2015 Apr 24;15:35. doi: 10.1186/s12894-015-0029-2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse events categorised according to the NCI-CTAE in grade 1 to 5 | week 12 | Yes | |
Other | Grading of complications according to Clavien classification | week 12 | Yes | |
Primary | Absorption volume of irrigation fluid during the Thulium laser TUV-P | shortly after Thulium laser TUV-P | No | |
Secondary | Duration of surgery | at time of start and of end of surgery | No | |
Secondary | Does absorption of irrigation fluid occur? | yes: any detection of alcohol in the expired breath | at time of surgery | No |
Secondary | Assessment of bleeding and relevant intraoperative events (capsular perforation, injury to prostatic sinuses or deep bladder neck incision) by the surgeon | at time of surgery | Yes | |
Secondary | Amount of laser energy used intraoperatively (kilojoules) | at time of end of surgery | No | |
Secondary | Pre- to postoperative changes in serum biochemical and haematological variables (creatinin, sodium, potassium, chloride), venous pH, haemoglobin | 30 min after intervention | No | |
Secondary | Pre- to postoperative changes in flow and residual urine | 12 weeks after intervention | No | |
Secondary | Total irrigation volume and volume of all administered i.v. fluids | at time of end of surgery | No | |
Secondary | Duration of hospitalization post procedure | participants will be followed for the duration of hospital stay, an expected average of 1 week | No | |
Secondary | Duration of post procedure catheterization | at time of end of catheterization, an expected average of 48 hrs | No | |
Secondary | Pre- to postoperative changes in the IPSS | 12 weeks after intervention | No | |
Secondary | Pre- to postoperative changes in bladder diary | 12 weeks after intervention | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03052049 -
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
|
N/A | |
Recruiting |
NCT04757116 -
Post-Market Study to Assess iTind Safety in Comparison to UroLift
|
N/A | |
Completed |
NCT03460873 -
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
|
||
Completed |
NCT01218243 -
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
|
Phase 2 | |
Completed |
NCT01566292 -
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00407953 -
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
|
Phase 4 | |
Completed |
NCT03191734 -
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
N/A | |
Recruiting |
NCT04838769 -
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
|
N/A | |
Completed |
NCT03856242 -
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
|
Phase 4 | |
Completed |
NCT04032067 -
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT02505919 -
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
|
N/A | |
Completed |
NCT02855892 -
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
|
Phase 2 | |
Completed |
NCT02145208 -
Study to Assess the Efficacy of Medi-Tate iTind Device
|
N/A | |
Completed |
NCT00970632 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
|
Phase 3 | |
Recruiting |
NCT02592473 -
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00945490 -
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
|
Phase 3 | |
Completed |
NCT00759135 -
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
|
Phase 2 | |
Completed |
NCT00224107 -
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
|
Phase 3 | |
Recruiting |
NCT04648176 -
Application of MOSES Technology in BPH
|
N/A | |
Terminated |
NCT00651807 -
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
|
Phase 2 |